Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Rapid Micro Biosystems (RPID) Operating Expenses (2020 - 2025)

Rapid Micro Biosystems' Operating Expenses history spans 6 years, with the latest figure at $23.5 million for Q4 2025.

  • On a quarterly basis, Operating Expenses rose 27.35% to $23.5 million in Q4 2025 year-over-year; TTM through Dec 2025 was $81.0 million, a 3.86% increase, with the full-year FY2025 number at $81.0 million, up 3.86% from a year prior.
  • Operating Expenses hit $23.5 million in Q4 2025 for Rapid Micro Biosystems, up from $19.2 million in the prior quarter.
  • Over the last five years, Operating Expenses for RPID hit a ceiling of $23.5 million in Q4 2025 and a floor of $14.7 million in Q1 2021.
  • Historically, Operating Expenses has averaged $19.4 million across 5 years, with a median of $19.5 million in 2024.
  • Biggest five-year swings in Operating Expenses: surged 97.47% in 2021 and later decreased 14.37% in 2023.
  • Tracing RPID's Operating Expenses over 5 years: stood at $19.8 million in 2021, then rose by 9.46% to $21.6 million in 2022, then decreased by 14.37% to $18.5 million in 2023, then decreased by 0.42% to $18.4 million in 2024, then rose by 27.35% to $23.5 million in 2025.
  • Business Quant data shows Operating Expenses for RPID at $23.5 million in Q4 2025, $19.2 million in Q3 2025, and $19.4 million in Q2 2025.